Comparison of Early Recurrence after Microwave Ablation for Liver Metastases of Colorectal Cancer Guided by Different Imaging Techniques Based on Propensity Score Matching
-
摘要:
目的 分析CT与超声引导下结直肠癌肝转移微波消融术后的早期复发情况。 方法 回顾性分析2018年1月至2021年1月云南省肿瘤医院行微波消融治疗(microwave ablation,MWA)的结直肠癌肝转移(colorectal cancer liver metastases,CRCLM)患者137例,其中CT组60例,超声组77例。运用1∶1倾向性得分匹配(propensity score matching,PSM),平衡2组基线,最终纳入CT组25例,超声组25例。比较两组患者靶病灶术后早期复发情况、靶病灶中位无病生存期(disease-free survival,DFS)。 结果 两组患者术后早期复发情况为CT组6例(24.0%),超声组14例(56.0%),两组复发情况差异有统计学意义(P = 0.021)。CT组患者的DFS时间为201.6 d[95%CI172.9-230.3],超声组的中位DFS时间为146.0 d[95%CI108.2-183.7](P = 0.033)。 结论 在CRCLM使用MWA治疗的患者中,CT组的复发率低于超声组;对于中位无病生存期而言,CT组较超声组有其更好的疗效优势。 Abstract:Objectives To analyze and compare the early recurrence of colorectal cancer after microwave ablation for liver metastases guided by CT and ultrasound. To Methods A total of 137 cases of colorectal cancer liver metastases (CRCLM) treated in Yunnan Cancer Hospital from January 2018 to January 2021 after microwave ablation (MWA) were retrospectively analyzed, including 60 cases in the CT group and 77 cases in the ultrasound group. The baseline of the two groups was balanced using 1:1 propensity score matching (PSM), resulting in 25 cases in the CT group and 25 cases in the ultrasound group. The early postoperative recurrence of target lesions and the median disease-free survival (DFS) of target lesions were compared between the two groups. Results The early recurrence rates in the two groups were 6 cases (24.0%) in the CT group and 14 cases (56.0%) in the ultrasound group, with a statistically significant difference between the two groups (P = 0.021). The median DFS time for the CT group was 201.6 days [95%CI172.9-230.3], while the median DFS time for the ultrasound group was 146.0 days [95%CI108.2-183.7](P = 0.033). Conclusions In patients with CRCLM treated with MWA, the recurrence rate in CT group is lower than that in ultrasound group. In terms of median disease-free survival, the CT group had a better curative effect than the ultrasound group. -
表 1 PSM前后患者基线特征资料[ M(IQR)/n(%)]
Table 1. Baseline characteristics of patients before and after PSM[ M(IQR)/n(%)]
项目 PSM前 PSM后 CT组
(n=60)超声组
(n=77)χ2/Z P CT组
(n=25)超声组
(n=25)χ2/Z P值 性别 1.074 0.300 0.368 0.544 男 41(68.3) 46(59.7) 18(72.0) 16(64.0) 女 19(31.7) 31(40.3) 7(28.0) 9(36.0) ECOG 1.004 0.316 0.000 1.000 0 2(3.3) 7(9.1) 0 1(4.0) 1 58(96.7) 70(90.9) 25(100.0) 24(96.0) 原发病灶位置 6.358 0.012* 0.000 1.000 左侧结直肠 54(90.0) 56(72.7) 20(80.0) 21(84.0) 右侧结肠 6(10.0) 21(27.3) 5(20.0) 4(16.0) 病理类型 1.190 0.275 0.802 0.370 未/低分化 42(70.0) 47(61.0) 18(72.0) 15(60.0) 中/高分化 18(30.0) 30(39.0) 7(28.0) 10(40.0) 单病灶消融 15.288 <0.001* 1.471 0.225 是 22(36.7) 54(70.1) 15(60.0) 19(76.0) 否 38(63.3) 23(29.9) 10(40.0) 6(24.0) 病灶形态 2.518 0.113 1.754 0.185 类圆形 45(75.0) 66(85.7) 21(84.0) 17(68.0) 非类圆形 25(25.0) 11(14.3) 4(16.0) 8(32.0) 病灶距离包膜距离 0.555 0.456 0.325 0.569 <0.5 cm 35(58.3) 40(51.9) 13(52.0) 15(60.0) ≥0.5 cm 25(41.7) 37(48.1) 12(48.0) 10(40.0) 术后疼痛时间 0.026 0.873 0.000 1.000 <3 h 52(86.7) 66(85,7) 23(92.0) 22(88.0) ≥3 h 8(13.3) 11(14.3) 2(8.0) 3(12.0) 年龄[岁] 59
(52.50,68.75)60
(49,64)−1.771 0.077 58
(52.00,66.00)62
(42.00,72.40)−1.253 0.210 术前CEA[mmol/L] 6.76
(3.41,25.89)3.67
(2.58,6.49)−3.476 <0.001* 3.37
(2.40,4.73)6.37
(2.60,27.72)−2.989 0.430 术前CA199[mmol/L] 22.23
(9.07,29.08)13.84
(9.24,24.35)−1.156 0.248 15.27
(10.70,28.56)24.52
(2.01,35.824)−0.340 0.734 术前CA242[mmol/L] 8.64
(1.95,16.78)8.51
(4.88,14.40)−0.588 0.557 8.64
(1.65,15.43)10.62
(0.64,23.824)−1.679 0.093 *P < 0.05。 表 2 CRCLM患者消融术后复发情况[n(%)]
Table 2. Recurrence of CRCLM patients after ablation[n(%)]
复发情况 PSM前 PSM后 CT组
(n=60)超声组
(n=77)χ2 P CT组
(n=25)超声组
(n=25)χ2 P 5.386 0.020* 5.333 0.021* 未复发 45(75.0) 43(55.8) 19(76.0) 11(44.0) 复发 15(25.0) 34(44.2) 6(24.0) 14(56.0) *P < 0.05。 -
[1] Siegel R L,Wagle N S,Cercek A,et al. Colorectal cancer statistics,2023[J]. CA Cancer J Clin,2023,73(3):233-254. doi: 10.3322/caac.21772 [2] 刘宗超,李哲轩,张阳,等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志,2021,7(2):1-14. [3] Mitchell D,Puckett Y,Nguyen Q N. Literature review of current management of colorectal liver metastasis[J]. Cureus,2019,11(1):e3940. [4] Dijkstra M,Nieuwenhuizen S,Puijk R S,et al. Thermal ablation compared to partial hepatectomy for recurrent colorectal liver metastases: An amsterdam colorectal liver met registry (AmCORE) based study [J]. Cancers (Basel),2021,13(11). 补充页码 [5] Philips P,Groeschl R T,Hanna E M,et al. Single-stage resection and microwave ablation for bilobar colorectal liver metastases[J]. Br J Surg,2016,103(8):1048-1054. doi: 10.1002/bjs.10159 [6] Pathak S,Jones R,Tang J M,et al. Ablative therapies for colorectal liver metastases: A systematic review[J]. Colorectal Dis,2011,13(9):e252-265. doi: 10.1111/j.1463-1318.2011.02695.x [7] Pillai K,Akhter J,Chua T C,et al. Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency,bipolar radiofrequency,and microwave,using ex vivo calf liver model[J]. Medicine (Baltimore),2015,94(9):e580. [8] Luo M,Chen S L,Chen J,et al. Resection vs. ablation for lesions characterized as resectable-ablative within the colorectal liver oligometastases criteria: A propensity score matching from retrospective study[J]. PeerJ,2020,8:e8398. doi: 10.7717/peerj.8398 [9] 胡志强,游伟程,潘凯枫,等. 中、美两国癌症流行特征分析——《2023美国癌症统计报告》解读[J]. 科技导报,2023,41(18):18-28. [10] Oki E,Ando K,Nakanishi R,et al. Recent advances in treatment for colorectal liver metastasis[J]. Ann Gastroenterol Surg,2018,2(3):167-175. doi: 10.1002/ags3.12071 [11] Huang Z,Pan Y,Zhou P,et al. Long-term outcomes of ultrasound-guided percutaneous microwave ablation versus resection for colorectal cancer liver metastases: A propensity-score matched study[J]. Int J Hyperthermia,2021,38(1):1276-1284. doi: 10.1080/02656736.2021.1968511 [12] Gillams A,Goldberg N,Ahmed M,et al. Thermal ablation of colorectal liver metastases: A position paper by an international panel of ablation experts,the interventional oncology sans frontières meeting 2013[J]. Eur Radiol,2015,25(12):3438-3454. doi: 10.1007/s00330-015-3779-z [13] 刘广健,覃斯,陈秋,等. 超声引导经皮微波消融治疗结直肠癌肝转移瘤单中心五年并发症分析[C]. 中国超声医学工程学会第五届全国介入超声医学学术交流大会,中国北京,2019 . [14] 姚全军,黎海亮,郭晨阳,等. CT引导微波治疗难治性结直肠癌肝转移的临床研究[J]. 实用医学杂志,2012,28(15):2565-2567. doi: 10.3969/j.issn.1006-5725.2012.15.037 [15] 田一禾,刘宏,白亮彩. 结直肠癌肝转移的影像学评估研究进展[J]. 磁共振成像,2023,14(2):191-196. doi: 10.12015/issn.1674-8034.2023.02.034 [16] 李丽珍,钟秋红,黄昌辉,等. 超声引导下经皮微波消融与CT超声引导下肿瘤射频消融治疗原发性肝癌的临床比较[J]. 中国CT和MRI杂志,2017,15(1):76-78+82. doi: 10.3969/j.issn.1672-5131.2017.01.024 [17] 朱德祥,任黎,许剑民. 中国结直肠癌肝转移诊断和综合治疗指南(2023版)[J]. 消化肿瘤杂志(电子版),2023,15(2):86-99. [18] 潘宇,周荷英,秦远红,等. 结直肠癌肝转移患者微波消融术后肝内无进展生存期列线图模型及其预测价值[J]. 介入放射学杂志,2023,32(11):1088-1095. doi: 10.3969/j.issn.1008-794X.2023.11.007